T. Rowe Price Associates’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $69.5M | Sell |
|
|||||
|
2025
Q2 | $105M | Sell |
|
|||||
|
2025
Q1 | $117M | Buy |
|
|||||
|
2024
Q4 | $106M | Sell |
|
|||||
|
2024
Q3 | $170M | Buy |
|
|||||
|
2024
Q2 | $123M | Sell |
|
|||||
|
2024
Q1 | $167M | Buy |
|
|||||
|
2023
Q4 | $165M | Buy |
|
|||||
|
2023
Q3 | $113M | Sell |
|
|||||
|
2023
Q2 | $167M | Buy |
|
|||||
|
2023
Q1 | $142M | Sell |
|
|||||
|
2022
Q4 | $190M | Sell |
|
|||||
|
2022
Q3 | $197M | Sell |
|
|||||
|
2022
Q2 | $643M | Sell |
|
|||||
|
2022
Q1 | $863M | Buy |
|
|||||
|
2021
Q4 | $969M | Buy |
|
|||||
|
2021
Q3 | $1.03B | Buy |
|
|||||
|
2021
Q2 | $1.05B | Buy |
|
|||||
|
2021
Q1 | $1.22B | Buy |
|
|||||
|
2020
Q4 | $1.31B | Buy |
|
|||||
|
2020
Q3 | $686M | Buy |
|
|||||
|
2020
Q2 | $600M | Buy |
|
|||||
|
2020
Q1 | $209M | Buy |
|
|||||
|
2019
Q4 | $192M | Buy |
|
|||||
|
2019
Q3 | $191M | Sell |
|
|||||
|
2019
Q2 | $293M | Buy |
|
|||||
|
2019
Q1 | $243M | Buy |
|
|||||
|
2018
Q4 | $119M | Sell |
|
|||||
|
2018
Q3 | $212M | Sell |
|
|||||
|
2018
Q2 | $215M | Buy |
|
|||||
|
2018
Q1 | $115M | Buy |
|
|||||
|
2017
Q4 | $98.4M | Buy |
|
|||||
|
2017
Q3 | $86.5M | Sell |
|
|||||
|
2017
Q2 | $109M | Buy |
|
|||||
|
2017
Q1 | $113M | Buy |
|
|||||
|
2016
Q4 | $117M | Sell |
|
|||||
|
2016
Q3 | $130M | Buy |
|
|||||
|
2016
Q2 | $77.9M | Buy |
|
|||||
|
2016
Q1 | $85.4M | Sell |
|
|||||
|
2015
Q4 | $152M | Sell |
|
|||||
|
2015
Q3 | $131M | Buy |
|
|||||
|
2015
Q2 | $121M | Sell |
|
|||||
|
2015
Q1 | $77.4M | Sell |
|
|||||
|
2014
Q4 | $57.8M | Sell |
|
|||||
|
2014
Q3 | $74.5M | Buy |
|
|||||
|
2014
Q2 | $53.7M | Sell |
|
|||||
|
2014
Q1 | $65.2M | Buy |
|